and IBDU patients. 2.5% were off medication. 55 patients (33%) were in remission on monotherapy [5\erhyphen;ASAs n = 16, Azathioprine/6-MP n = 28 (27/1), Methotrexate n = 5, Infliximab n = 3 and Adalimumab n = 3]. 107 (64%) were on combination therapy [Azathioprine/6-MP and 5-ASA n = 45 (42/3), Azathioprine and Infliximab n = 15, 6-MP and Infliximab n = 1, Azathioprine and Adalimumab n = 5, Methotrexate and Infliximab n = 1, Methotrexate and Adalimumab n = 3, Methotrexate and 5-ASA n = 3, 5-ASA, Azathioprine and Infliximab n = 11, 5-ASA, Azathioprine and Adalimumab n = 6]. 17/107 (16%) children were on other combinations. Conclusion: Overall 80.5% of our patients were in clinical remission, of whom one third were on monotherapy only. Our ICN database is a very valuable tool in capturing our remission rates on mono-and combination therapies, alerting us on treatment failures.
P-033
Data on surgery in paediatric IBD (pIBD) over a 4 year period using the ImproveCareNow (ICN) collaboration data base Introduction: The natural history pIBD is multifactorial, colectomy rates (CR) up to 20% are reported. Previous data on UC patients (P) at this center were 3.6%. After joining ICN clinical outcomes were benchmarked against 66 other pIBD centres. Aim: Our aim was to review surgical outcomes in pIBD patients since joining ICN. Methods: All surgical procedures peformed were captured from our ICN database over a 4 year period in 270 patients (154 male, range 0.4 16 y, median 9.7 y). Results: All patients received standard pIBD treatment, escalating to monoclonal treatment (MT) on relapse. This aggressive approach lead to 5 (1.85%) of 270 IBD patients requiring surgery. P1 (15 y) had intractable fistulating Crohn's disease (CD) requiring a laparoscopic total colectomy/terminal ileum (TI) resection, developing peristomal fistulae, requiring further revision. P2 (13 y) with Crohn's-like pIBD had spontaneous perforation, needing defunctioning ileostomy. P3 (11 y) had intractable ulcerative colitis (UC, 1/66, 1.64%) requiring subtotal colectomy (STC). P4 (14 y) had IBD unclassified (IBDU) with CD-like features with transfusion dependence, requiring STC/ileostomy formation. P5 (8 y) had intractable right-sided/TI CD requring right hemicolectomy/loop ileostomy formation. Due to on-going small bowel inflammation, stoma ulcerations and rectal prolapse, stem cell transplant treatment was given and restoratory surgery at our centre was performed one year later achieving continuity. Conclusion: In our institution only 1.85% of patients identified within the ICN database required surgical interventions after having received aggressive immunomodulatory and immunosuppressive treatment. 
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